## HSIC: Henry Schein, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -4.3% below STRENGTH zone (3.0-6.0%); PEG 1.49 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-7.0% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($68.21)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 7, Bearish: 0)

**1. Henry Schein expands vVARDIS distribution deal for drill-free cavity treatment**
- Source: Investing.com India | 20251202T031600 | Bullish | Relevance: 99%
- Henry Schein, Inc. has expanded its exclusive distribution agreement with Swiss company vVARDIS for Curodont Repair Fluoride Plus, a drill-free cavity treatment, across all U.S. dental market segments starting January 1, 2026. This expansion builds on a previous limited exclusivity agreement and now includes general dentistry, orthodontics, and pediatric dentistry. The product has already seen significant adoption and is highlighted as a key driver for Henry Schein's continued strength in the dental supplies market, following a strong third-quarter 2025 earnings report.

**2. Henry Schein expands vVARDIS distribution deal for drill-free cavity treatment**
- Source: Investing.com Australia | 20251202T084600 | Bullish | Relevance: 99%
- Henry Schein, Inc. has expanded its exclusive U.S. distribution agreement with vVARDIS for Curodont Repair Fluoride Plus, a drill-free cavity treatment. The expanded deal, effective January 1, 2026, will cover all dental market segments, extending beyond Dental Service Organizations to general, orthodontic, and pediatric dentistry nationwide. This move aims to enhance access to the product, which has already treated over 500,000 patients and aligns with Henry Schein's commitment to advancing oral health.

**3. Henry Schein expands vVARDIS distribution deal for drill-free cavity treatment**
- Source: Investing.com Nigeria | 20251201T224600 | Bullish | Relevance: 99%
- Henry Schein, Inc. has expanded its exclusive U.S. distribution agreement with vVARDIS for Curodont Repair Fluoride Plus, a drill-free cavity treatment, to cover all dental market segments starting January 1, 2026. This expansion builds on a successful prior partnership and aims to reach broader dental practices and address the high prevalence of early-stage cavities. The announcement follows Henry Schein's strong third-quarter 2025 earnings, which surpassed analyst expectations.

**4. Is There Opportunity in Henry Schein After 18% Rally and Digital Dentistry Expansion?**
- Source: Simply Wall Street | 20251201T045231 | Somewhat-Bullish | Relevance: 99%
- Henry Schein's stock recently rallied 18%, sparking debate on its future growth and risk. The company shows a strong valuation score of 5 out of 6 according to Simply Wall St's valuation checks, and a Discounted Cash Flow (DCF) analysis suggests it is significantly undervalued by 57.2%. Its Price-to-Earnings (PE) ratio is currently 22.45x, suggesting it is about fairly valued when compared to its tailored "Fair Ratio" of 24.99x.

**5. Henry Schein (Nasdaq: HSIC) to be exclusive US Curodont distributor across dental market**
- Source: Stock Titan | 20251201T213400 | Bullish | Relevance: 99%
- Henry Schein, Inc. has expanded its partnership with vVARDIS, gaining exclusive U.S. distribution rights for the Curodont™ Repair Fluoride Plus product across all dental market segments, effective January 1, 2026. This expansion builds on a previous agreement for Dental Service Organizations and will now cover general dentistry, orthodontics, and pediatric dentistry nationwide. Curodont™ is a drill-free, needle-free solution for early-stage cavities, addressing a significant unmet need in oral health.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $86 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 0 ($0.00M) |
| Sells | 4 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 64.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 4 |

**Top Holders:**
- Kohlberg Kravis Robe: 13.3% (0.0%)
- JPMORGAN CHASE & CO: 10.6% (+98.6%)
- Vanguard Group Inc: 10.2% (-7.2%)
- Artisan Partners Lim: 5.8% (+5.7%)
- Blackrock Inc.: 5.7% (-8.6%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-7.0% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.49 suggests fair value with growth premium. Institutional flow bullish (5 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $9.2B |
| Beta | 0.89 |
| 52W Range | $60.56 - $82.49 |
| Short Interest | 7.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.49 |
| Forward P/E | 13.6 |
| Current P/E | 14.6 |
| YoY Growth | 7.6% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 2.7% to -4.3% (-7.0% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 7.3pp (needs >3.0% for momentum thesis). Underperforming sector by 4.1pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.03x) but short-term weakness (below SMA20). RSI neutral at 53.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -4.32% (CS: 10) | Weak |
| RSI_14 | 52.8 | Neutral |
| MACD Histogram | -0.15 | Bearish |
| vs SMA20 | 0.987x | Below |
| vs SMA50 | 1.058x | Above |
| vs SMA200 | 1.034x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $71.67
- **Stop Loss:** $68.21 (4.8% risk)
- **Target:** $75.13 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 289
- **Position Value:** $20,712.63
- **Portfolio %:** 20.71%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate improvement trajectory. VIX compression from 20.5 to 16.6 over 5 days signals declining fear, while 47% breadth shows narrow but recovering participation. Fed meeting in 6 days creates near-term uncertainty, but AI sector momentum and improving technical setups support selective positioning.*

### Earnings

**Next:** 2026-02-24 (Est: $1.30)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.28 | $1.38 | +7.9% |
| 2025Q2 | $1.19 | $1.10 | -7.6% |
| 2025Q1 | $1.11 | $1.15 | +3.6% |
| 2024Q4 | $1.21 | $1.19 | -1.6% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*